- 1 Title. An ST131 clade and a Phylogroup A clade bearing a novel Escherichia coli O-antigen
- 2 cluster predominate among bloodstream E. coli isolates from southwest Nigeria hospitals.
- Ayorinde O. Afolayan¹, Aaron O. Aboderin², Anderson O. Oaikhena¹, Erkison Ewomazino 4
- Odih¹, Veronica O. Ogunleye³, Adeyemi T. Adeyemo⁴, Abolaji T. Adeyemo⁵, Oyeniyi S. 5
- Bejide¹, Anthony Underwood⁶, Silvia Argimón⁶, Monica Abrudan⁶, Abiodun Egwuenu⁷, Chikwe 6
- Ihekweazu⁷, David M. Aanensen⁶ and Iruka N. Okeke^{1*}. 7
- 9 ¹Global Health Research Unit for the Genomic Surveillance of Antimicrobial Resistance,
- 10 Department of Pharmaceutical Microbiology, Faculty of Pharmacy, University of Ibadan, Oyo
- 11 State, Nigeria.

8

- 12 ²Department of Medical Microbiology and Parasitology, Obafemi Awolowo University Teaching
- 13 Hospitals Complex, Ile-Ife, Osun State, Nigeria.
- 14 ³Department of Medical Microbiology and Parasitology, University College Hospital, Ibadan,
- 15 Oyo State, Nigeria.
- 16 ⁴Department of Medical Microbiology and Parasitology, Obafemi Awolowo University Teaching
- 17 Hospitals Complex, Ile-Ife, Osun State, Nigeria.
- 18 ⁵Department of Medical Microbiology and Parasitology, University of Osun Teaching Hospital,
- 19 Osogbo, Osun State, Nigeria.
- 20 ⁶Centre for Genomic Pathogen Surveillance, Big Data Institute, University of Oxford, Old Road
- 21 Campus, Oxford, United Kingdom and Wellcome Genome Campus, Hinxton, UK.
- 22 ⁷Nigeria Centre for Disease Control, Jabi, Abuja, Nigeria.
- 24 *Corresponding author: Iruka N. Okeke. Department of Pharmaceutical Microbiology,
- 25 Faculty of Pharmacy, University of Ibadan, Oyo State, Nigeria. +234 805 328 1714.
- 26 iruka.n.okeke@gmail.com

Abstract

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46 47 48

50

51

57

58

Escherichia coli bloodstream infections are typically attributed to a limited number of lineages that carry virulence factors associated with invasion and, in recent years, are increasingly multiply antimicrobial resistant. In Nigeria, E. coli is a common cause of bloodstream infections but the identity of circulating clones is largely unknown and surveillance of their antimicrobial resistance has been limited. We verified, susceptibility-tested and whole genome-sequenced 68 bloodstream E. coli isolates recovered between 2016 and 2018 at three sentinel sites in southwestern Nigeria. Resistance to antimicrobials commonly used in Nigeria was high, reaching 100 % (n = 67) for trimethoprim, 92.5 % (n = 62) for ampicillin, 79.1 % (n = 53) for ciprofloxacin, and 55.2 % (n = 37) for aminoglycosides. All the isolates were susceptible to carbapenems and colistin. The strain set included isolates from globally disseminated high risk clones including those belonging to ST12 (n=2), ST131 (n=12) and ST648 (n = 4). Twenty-three (33.82%) of the isolates clustered within two clades. The first of these consisted of ST131 strains, comprised of O16:H5 and O25:H4 sub-lineages. The second was an ST10-ST167 complex clade comprised of strains carrying capsular genes that may have originated in Klebsiella. We additionally determined that four ST90 strains from one sentinel represented a retrospectively detected outbreak. Our data demonstrate that a broad repertoire of invasive E. coli isolates cause bloodstream infections in southwest Nigeria. In addition to pandemic lineages, particularly ST131, these include a previously undescribed lineage. Genomic surveillance is valuable for tracking these and other clones and for outbreak identification.

- Keywords: Escherichia coli, Genomic Surveillance, ST131, antimicrobial resistance, cpsACP,
- 49 Nigeria

Data Summary

- 52 Phylogenetic tree, clinical data, and epidemiological data were visualized using Microreact
- 53 (https://microreact.org/project/NigeriaEcoliInvasive/d0dc3660) and Phandango (for visualization
- of pangenome, tree, and metadata). All the sequence data have been deposited in the ENA under
- 55 the project ID PRJEB29739 (https://www.ebi.ac.uk/ena/browser/view/PRJEB29739). Accessions
- 56 can be found in Table S6.

Introduction

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

Extra-intestinal pathogenic Escherichia coli (ExPEC) are responsible for the majority of infections in the blood, urine, meninges, prostate, and other normally sterile sites [1–3]. Although typically initially acquired within the gastrointestinal tract (and less commonly via genital route), these strains of E. coli differ from commensal and diarrhoegenic E. coli in possession of factors associated with systemic virulence [4, 5], allowing them to survive in different extra-intestinal niches. Some of the virulence genes associated with ExPEC include adhesins (fim, pap, sfa, afa), invasins (ibeA), iron acquisition genes (ybt, iro, iuc), toxins (clb, cnf, hly, SPATE genes) and protectins (traT, ompT, kpsMT), among others [4, 5]. ExPEC also often have K, O and H antigens that make them recognizable to E. coli experts and, in some instances, assist them in evading immune responses. Virulence and AMR determinants, as well as negative frequency-dependent selection, likely influence the stability of the most dominant ExPEC groups, which are often multiply resistant [6], thereby sustaining the occurrence of extraintestinal diseases globally. In Africa, available data reveal that there is an upward trend in the prevalence of globally dominant ExPEC lineages in humans [7] and animals [8], painting a grim picture for disease and antimicrobial resistance. Robust surveillance is urgently needed to tackle antimicrobial resistance in a more robust and consistent manner within each country. Whole genome sequencing (WGS) has helped to provide a clearer picture on the epidemiology of infectious diseases caused by ExPEC and has identified a number of pandemic clones. Incorporation of WGS with existing epidemiological frameworks in national public health institutes is critical for providing genomic context for prospective surveillance and for designing and implementing AMR-eliminating strategies. Although studies conducted in Africa and other low- and middle-income countries (LMICs) have shown the abundance of invasive E. coli [9, 10], these studies are too few and far between so that ExPEC and AMR epidemiology are poorly understood [7, 11]. In Nigeria, there is sparse molecular information on ExPEC, but a few studies point to likely clonal expansion of resistant lineages and local presence of pandemic clones of concern [12–16]. These studies provide valuable information but represent an insufficient picture of ExPEC clones in Nigeria with few data available from South. To extend the body of knowledge on genomic epidemiology of ExPEC in south western Nigeria, including AMR patterns and mechanisms, we leveraged on our

existing genomic surveillance of bacterial AMR efforts by characterizing the genomes of invasive isolates from tertiary hospitals in South-west Nigeria.

Methodology

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

Species Validation and Antimicrobial Susceptibility Tests

Sentinel hospital laboratories sent in anonymized clinical data and invasive E. coli isolates collected between the years 2016 to 2018 to the National Reference Laboratory for verification of isolate identity and antimicrobial susceptibility tests (AST). Isolate identity and AST were achieved using the VITEK2 Instrument. Drugs tested include; amikacin (AMK), gentamicin (GEN), ampicillin (AMP), amoxicillin/clavulanic acid (AMC), piperacillin/tazobactam (TZP), cefuroxime (CXM), cefuroxime axetil (CXMA), cefepime (FEP), ceftriaxone (CRO), cefoperazone/sulbactam (SFP), nitrofurantoin (NIT), nalidixic acid (NAL), ciprofloxacin (CIP), ertapenem (ERT), imipenem (IPM), meropenem (MEM), and trimethoprim-sulphamethoxazole (SXT). Resistance profiles were generated from VITEK2 AST data. Minimum Inhibitory Concentration values were converted to RIS values and the bug-drug combination table was generated using the AMR R package (v1.4.0; https://github.com/msberends/AMR) [17]. Antibiotic susceptibility patterns were determined in line with the CLSI 2019 standards [18].

Biofilm Assay

- 109 Following Wakimoto's procedure [19], we sub-cultured invasive E. coli strains overnight in LB 110 broth at 37°C with shaking at 160 rpm. Afterwards, we measured 190 µL of Dulbecco's 111 Modified Eagle's Medium (DMEM) containing 0.45 % glucose using a pipette into each well of 112 a 96-well plate (different plates were used for each time point (3h, 6h, 12h, 24 h)). Five µL of 113 each isolate was inoculated in triplicate per time point into a 96-well plate from the stock plate
- 114 and incubated at 37°C without shaking until each time point was reached. Absorbance at 595 nm
- 115 was taken on completion of time point.
- 116 We pipetted spent media out of the 96-well plates. Each well was washed with PBS three times,
- 117 fixed (10 mins, 200 µL of 75% ethanol), dried, and stained with 195 µL of 0.5 % crystal violet

for 5 minutes. This was followed by washing and drying of the plates. We added 200 μL of 95% ethanol to each well, allowed the wells to stand for 20 minutes at room temperature, and determined absorbance with an enzyme linked immunosorbent assay (ELISA) plate reader at 570 nm. Biofilm index was defined using the average of the values for the optical density (OD) at 570 nm and 595 nm, and was calculated by dividing the OD values for each strain at a given timepoint by the OD values of the negative control at the given timepoint [20]. Enteroaggregative *E. coli* strains 042 was used as positive control while *E. coli* K-12 DH5α was used as negative control.

Haemolysis Test

We sub-cultured invasive strains in LB broth at 37°C with shaking at 160 rpm overnight, and transferred the mixture into 96-well plates where each well was assigned to each isolate. We inoculated the surface of the blood agar with the invasive strains and control. Alpha haemolysis and beta haemolysis is indicated by a green colouration and a clear zone around bacteria colonies, respectively.

DNA Extraction, Library Preparation, and Whole Genome Sequencing

Genomic DNA was extracted following the protocol outlined in a previous report [21]. Briefly, the Wizard DNA extraction kit (Promega; Wisconsin, USA; Cat. No: A1125) was used in the extraction of genomic DNA of all isolates. A dsDNA Broad Range quantification assay was used in the quantification of DNA extracts (Invitrogen; California, USA; Cat. No: Q32853). DNA libraries were prepared and sequenced using the NEBNext Ultra II FS DNA library kit (New England Biolabs, Massachusetts, USA; Cat. No: E6617L) and Illumina HiSeq X10 instrument (Illumina, CA, USA), respectively.

Genome Assembly and Speciation

Raw sequence reads were assembled using the GHRU pipeline (https://gitlab.com/cgps/ghru/pipelines/assembly) which is summarily explained by the GHRU de novo assembly protocol (https://www.protocols.io/view/ghru-genomic-surveillance-of-de-novo

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

antimicrobial-resista-bpn6mmhe). Speciation possible using Bactinspector was (https://gitlab.com/antunderwood/bactinspector/), implemented within the GHRU pipeline. **SNP Analysis and Phylogenetic Tree Generation** The Escherichia coli reference genome GCF 000285655.3 (ftp://ftp.ncbi.nlm.nih.gov/genomes/all/GCF/000/285/655/GCF 000285655.3 EC958.v1/GCF 0 00285655.3 EC958.v1 genomic.fna.gz) was used to infer a whole-genome alignment of the sequence reads. This step and other subsequent steps leading to the generation of a maximumlikelihood phylogenetic tree was done per the GHRU Mapping-based phylogeny protocol (https://www.protocols.io/view/ghru-genomic-surveillance-of-antimicrobial-resista-bpn6mmhe) which summarizes the steps implemented within the GHRU SNP phylogeny pipeline (https://gitlab.com/cgps/ghru/pipelines/snp_phylogeny). Isolates that clustered closely within the phylogenetic tree, belonged to the same ST, and shared similar resistance profiles, plasmid profiles, geography and dates of isolation, were investigated further for clue on potential outbreaks. We selected the closest reference genome to the outbreak isolates using Bactinspector, aligned the outbreak isolates (ST90) to the reference genome (NZ_CP010140.1), used Gubbins [22] to mask recombinant regions, and calculated pairwise **SNP** distances from the pseudo-genome alignment using **FastaDist** (https://gitlab.com/antunderwood/fastadist). Phylogenetic tree, epidemiological data and in silico data were visualized in Microreact [23] and Phandango [24]. AMR gene, Virulence gene, and Plasmid Replicon Prediction The program SRST2 (v0.2.0; https://github.com/katholt/srst2/) [25] and the ARGannot database (https://raw.githubusercontent.com/katholt/srst2/master/data/ARGannot r3.fasta) was used to screen raw sequence reads for the presence of acquired resistance genes. We also validated the report/output utilizing **GHRU AMR** Pipeline by the (https://gitlab.com/cgps/ghru/pipelines/dsl2/pipelines/amr_prediction) as explained briefly in this (https://www.protocols.io/view/ghru-genomic-surveillance-of-antimicrobial-resistaprotocol

bpn6mmhe). AmpC1 and AmpC2 were excluded from downstream analysis and visualization as

they are beta-lactamase genes present in almost all *E. coli* isolates and are unlikely to confer antibiotic resistance in *E. coli* [26]. Overall plot of resistance determinants was constructed using the *upset* function from the UpSetR package (v1.4.0) [27]. Plots of AMR genes stratified by sequence type and sentinel site were constructed using the ggupset package (v0.3.0). Association between virulence genes and phylogroups of *E. coli* was determined using the *fisher.test* function from the built-in Stats package in R (v4.1.0). Bar plots were visualized using the *ggplot* function from the Tidyverse package (v1.3.1) in R.

The raw reads were screened for virulence genes with the uses of the GHRU pipeline which utilizes ARIBA [28] and the VFDB database [29]. Plasmid replicons were determined by following the aforementioned GHRU protocol, which summarizes the use of ARIBA and the

MLST profiling

176

177

178

179

180

181

182

183

184

185

186

187

188

192

193

201

202

- Following the Achtman MLST scheme [30], multi-locus sequence types were determined using
- the SRST2 program. We confirmed the results by using the GHRU MLST pipeline (also follows
- the Achtman scheme) as summarized in the aforementioned GHRU protocol.

In silico Serotyping and Phylogroup Determination

PlasmidFinder database within the GHRU pipeline.

- The O and H serotypes of *Escherichia coli* were determined using the SRST2 program and the
- 195 EcOH database (https://raw.githubusercontent.com/katholt/srst2/master/data/EcOH.fasta). This
- result was validated using ECTyper (https://github.com/phac-nml/ecoli_serotyping) and
- 197 SerotypeFinder (https://bitbucket.org/genomicepidemiology/serotypefinder/src/master/).
- 198 SerotypeFinder utilizes KMA [31] and BLAST+ [32] to predict E. coli serotypes from the
- alignment of raw and assembled reads, respectively, against the SerotypeFinder database.
- 200 Escherichia coli genomes were assigned into phylogroups using ClermonTyping (v20.03) [33].

Concordance

The agreement between phenotypically-tested antimicrobial resistance and whole-genome sequenced-predicted antimicrobial resistance was determined for beta-lactams, cephalosporins, amikacin/kanamycin/gentamicin, trimethoprim, and the quinolones. Metrics such as sensitivity, specificity, true positives, true negatives, false positives, and false negatives were determined using a modified version (only input data was changed) of the R script (https://gitlab.com/snippets/2050300, first used in a previous report) which utilizes the *epi.tests* function within the epiR package (v2.0.26) for each antimicrobial tested. Here, "Sensitive" and "Intermediate" values were combined, taking cognizance of the arguments for and against the use of the term "Intermediate" in clinical settings [34].

Genome Annotation, Comparative Genomics, and gene location prediction.

- Functional annotation of Onovel32 clade genomes was performed using Bakta v1.0.4 [35].
- Genomes were compared and visualized using Artemis v18.1.0 [36], Artemis Comparison Tool
- v18.1.0 [37], and Clinker v0.0.21 [38]. The mlplasmid web tool [39] was used to predict whether
- 217 clinically-relevant virulence genes were borne on plasmids or on chromosomes.

Pangenome Analysis

203

204

205

206

207

208

209

210

211

212

213

218

219

227

228

229

- We utilized PROKKA-derived genome annotation files of each of the invasive E. coli genome
- assemblies as input for the generation of a pangenome using Panaroo (v1.2.3) [40]. Phandango
- 222 [24] was used to visualize the pangenome, tree, and metadata. We used the
- 223 find clade specific genes sub-command within the in-house script
- 224 (https://gitlab.com/bioinfo_erkison/panaroo_parser/-/blob/master/parse_panaroo.py) to identify
- and annotate clade-specific genes (genes found within 95% of the isolates belonging to the clade
- of interest and 5% of isolates outside the clade of interest).

Results

Epidemiology and Species Identification

- 230 Three hospital laboratories in South-west Nigeria submitted retrospective bloodstream
- 231 Escherichia coli isolates with clinical and epidemiological data between the years 2016 to 2018.
- Available data showed that isolates were collected from patients aged 1 day to 71 years, with 17
- 233 (25%) of the isolates recovered from children under 60 days old (range 1- 20 days, median 9
- days), who would be characterized as neonates. The isolates were submitted from the University
- College Hospital (UCH; n = 22), Obafemi Awolowo University (OAU) Teaching Hospitals
- Complex (n = 18), and Ladoke Akintola University (LAU; n = 28).
- Of the 68 invasive isolates confirmed as E. coli by whole-genome sequencing (WGS), 48
- 238 (70.6%) and 64 (94.1%) were correctly identified as E. coli by the sentinel biochemical testing
- and reference laboratory VITEK2, respectively. Escherichia coli isolates were often
- 240 misidentified as Klebsiella pneumoniae (n = 8) or Citrobacter freundii (n = 6) at the sentinel
- laboratories, while the VITEK2 system misidentified E. coli as Klebsiella pneumoniae (n = 3) or
- 242 Enterobacter aerogenes (n = 1).

244

Phylogroups, Serotypes, and Sequence Types of E. coli bloodstream isolates

- 245 E. coli sent from all three hospital sentinel laboratories spanned all E. coli phylogroups, with 18,
- 246 15, 19, 8, 2, 1, and 5 E. coli genomes classified within phylogroups A, B1, B2, C, D, E, and F,
- 247 respectively. The most common sequence types (ST) among the 33 identified STs include;
- 248 ST131 (n = 12), ST156 (n = 5), and 4 each of ST10, ST167 ST410, ST648, and ST90. These 7
- STs accounted for 54% of the E. coli isolates. Of these, only STs 131 and 167 were found across
- 250 the 3 sentinel sites (Figure 1a, Table S4). The three sentinel sites showed similar diversity of E.
- 251 coli belonging to several STs (OAU = 10 STs; LAU = 18 STs, UCH = 15 STs) (Table 1). While
- 252 ST131 genomes made up 63% of genomes within phylogroup B2 (the second most common
- 253 phylogroup), ST10 and ST167 genomes accounted for 44% of genomes within phylogroup A
- 254 (the most common phylogroup).
- 255 While none of the isolates were submitted as suspected outbreak strains, all four isolates
- belonging to the related STs 90 serotyped in *silico* as O8:H9, and were recovered from LAU
- within the same month (January, 2017). They carried the same plasmid profile (IncFI; IncFIA;
- 258 IncFIB AP001918; IncQ1), AMR gene profile, and similar but not identical resistance profile
- 259 (Figure 1b; Table S4). These four isolates were resistant to trimethoprim, the quinolones,

gentamicin, cefuroxime axetil, and ampicillin (Figure 1b, Table S3b). Intra-cluster pairwise comparison of SNPs revealed that two of the 4 isolates were identical while the other two isolates differed from these two isolates by 11 SNPs (the genome with the extra set of accessory genes) and 72 SNPs. Although these isolates were correctly identified within this sentinel site but cluster was only recognized retrospectively, likely due to different beta lactam resistance profiles.

- ST131 was the most common sequence type detected and the 12 isolates belonging to this ST
- clustered into two distinct lineages. They are the less-populated serotype H5 (n = 5; O16:H5)
- 269 lineage and the serotype H4 lineage (n = 7; O25:H4), henceforth referred to as the ST131 lineage
- 270 1 and ST131 lineage 2, respectively.

260

261

262

263

264

265

266

267

- A total of 38 unique serotypes were identified and 25 O-groups. Of note was the most common
- O-type, which was novel and identified in eleven isolates belonging to phylogroup A. These
- 273 ONovel:32 strains belonged to ST10 or ST167, or were single or double locus variants of these
- 274 STs. They included six ONovel32:H10 isolates as well as three H21 and one H4 –flagellin-
- encoding strains. Along with one ONT:H10 strain that also belonged to ST10, they formed a
- 276 distinct clade on the phylogenetic tree (Figure 1a). Strains belonging to this cluster were
- submitted from all three hospitals. Two of them were originally misclassified as *Klebsiella*
- 278 pneumoniae by VITEK at the reference laboratory level. Irrespective of whether the ST90
- outbreak clone is discounted, the ONovel:32 clade and the ST131 clade were the most abundant.
- Together they accounted for 32.4 % of the isolates and both clades were found in all three
- 281 hospitals (Figure 1a).

282283

Virulence Factor Profiles of the Bloodstream E. coli Isolates

- Diverse virulence genes were observed among the ExPEC genomes: 159 virulence-associated
- 285 (VAG) genes were found at least once in the 68 bloodstream isolates. Enterobactin genes (entB,
- 286 entC, entE_1, entS) and ferrienterobactin precursors and proteins (fep operon genes (ABCDEG)
- and fes_1), were found in more than 95% of the isolates. The outer membrane hemin receptor
- 288 (chu), siderophores (fyuA, irp, ybt), intimin-like adhesin (fdeC), haemolysin (hly), aerobactin
- 289 (iuc), polysialic acid transport protein kpsM_1, pyelonephritis-associated pili pap, SPATE genes

(*sat*, *vat*), and plasmid-encoded *Shigella* enterotoxin *senB* were more abundant and significantly more associated with phylogroup B2 than with phylogroups A, B1, and C (Fisher's exact Test, p < 0.05; Figure 2a). Figure 2b shows that a wide range of biofilm-forming capacities were seen in the subset of isolates tested with moderate or strong biofilm-formers being most common in phylogroups B1 and B2 as well as the ST90 outbreak strain-containing phylogroup C.

There were a number of clade-specific or clade-predominant virulence factors. Phylogroup B2 isolates, comprised largely of ST131 strains, carried the highest number of virulence genes (n = 86 VAGs). Thirty-five virulence genes were significantly more common in ST131 isolates than in non-ST131 isolates, where the genes of the outer membrane haem receptor (chu), versiniabactin (ybt), and pyelonephritis-associated pili (pap) operons compose 67% of these genes in more than 84% of the ST131 isolates (Fisher's exact Test, p < 0.05; Fig. 3a). On the other hand, 10 virulence genes were significantly more common in non-ST131 isolates than in ST131 isolates, including 8 genes (espX5, fimB_2, and gsp variants) present in more than 78% of the non-ST131 isolates, but less than 50% of ST131 isolates. The virulence genes entD, espL variants, espX variants, gnd, and ugd were absent in ST131 isolates but were present in at least 27% of non-ST131 isolates, notably ONovel32 strains (Fig. 3a). Both lineages of ST131 share common virulence genes, including; adhesins, yersiniabactin, aerobactin, enterotoxin, and transport-associated genes. However, several virulence genes are unique to each lineage. For example, the haemolysin (hly) carried by isolates within ST131 lineage 2 were absent in ST131 lineage 1. Also, two isolates within ST131 lineage 2 carried the cytotoxic necrotizing factor cnf1. More than half of isolates within the ST131 lineage 2 harbour cluster 3, while at least 1 isolate within ST131 lineage lineage 1 carried the *clbP* and *clbS* genes (Figure 3a and 3b).

None of the ONovel32 clade isolates carried alpha haemolysin or pyelonephritis associated pili genes that were present in some of the other lineages. However, some virulence genes were predominant among or restricted to ONovel32 strains (Figure 4a and 4b). These include the *esp4L* type III secretion effector, which was more common among these isolates than other phylogroup A strains as well as multiple genes encoding capsular modification enzymes. All the ONovel32 strains and one associated ONT strain carried a *ugd* gene. The only other isolates in

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

this collection with this gene were three isolates belonging to the globally disseminated high risk clone ST648 [41], known to possess biofilm-associated features that enhance pathogen emergence and persistence in both the human body and the environment. The ugd gene is associated with hypermucoviscosity and invasive virulence and the ONovel32 allele is 96% identical to that from K. pneumoniae NTUH-K2044, a hypervirulent K. pneumoniae isolate [42] and K. variicola (Accession number CP079802.1) capsular cluster ugd genes. ONovel:32 strains (but not the ONT:H10 strain in the same clade) carried cpsACP, a chromosomally-borne gene, which is predicted to encode a phosphatidic acid phosphatase (PAP2 Pfam 01569) family gene. PAP2 phosphatases replace phosphate groups on lipid A with amine groups resulting in a positively charged lipidA that confers resistance to cationic peptides [43]. PAP2 phosphatases have been known to be transmitted horizontally solitarily or as part of capsular clusters [44]. A BLAST search revealed that the ONovel32 PAP2 allele is 99.6% identical to endogenous PAP2 genes from *Klebsiella variicola* (Accession number CP079802.1). As shown in Figure 5, depicting the region for ONovel32 ST1284 strain OAU-VOA-056, cpsACP is located within a capsular gene cluster identical to a K. variicola cluster and flanked by a 5' IS3 transposase and a 3' IS1 protein InsB-encoding gene. At the opposite end of the cluster is the ugd gene. The cluster shows G+C content and other base-pattern signatures that depart from the *E. coli* flanking sequence (Figure 5a and 5b).

Observing that ONovel:32 cluster isolates, some of which were originally misclassified as Klebsiella, showed mucoidity upon plate culture, we sought to determine whether these strains had distinctive biofilm forming capacities. However, within the clade, although one cpsACP-positive strain was the outlying exceptional biofilm former, cpsACP-positive strains showed overall lower biofilm capacity. Median A_{570} in Figure 2 was 0.31 for phylogroup A strains lacking cpsACP and 0.21 for those with the gene. Both ONovel:32 non-biofilm formers and two of the three weak biofilm formers in this clade possessed the cpsACP gene.

Resistance Profiles (RP) and Concordance with Predicted Antimicrobial Resistance

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

Susceptibility testing of 67 out of the 68 isolates showed that, of the 16 antibiotics tested, resistance to trimethoprim-sulfamethoxazole (n = 67; 100%), ampicillin (n = 62; 92.5%), nalidixic acid (n = 57; 85.1%), and ciprofloxacin (n = 53; 79.1%) was commonly observed (Fig. 6a, Fig. 6b, Table S2). On the other hand, resistance to cefoperazone.sulbactam (n = 3; 4.5%) was less common. All isolates were susceptible to amikacin, ertapenem, imipenem (one strain showed "intermediate" phenotype), and meropenem. Resistance profiles were remarkably similar among the three sentinels (Figure 6b). Resistance to trimethoprim/sulfamethoxazole among isolates belonging to all 33 STs could be explained by the possession of dfrA (n = 54/67) and dfrB (n = 2/67) genes. Ciprofloxacin resistance (23 STs) was largely attributable to mutation in the quinolone resistance determining regions (QRDR) of gyrA (D87N, S83L), parC (E84A, E84G, E84K, S57T, S80I), and/or parE (E460D, I355T, I529L, I529L, I464F, L416F, L445H, S458A, S458T), with or without the presence of plasmid quinolone resistance genes (qnrS, qnrVC4, qepA, aac-(6')-Ib-cr). About 45% (n = 24/53) of isolates phenotypically resistant to ciprofloxacin carried a combination of aac(6')-lb-cr5 gene and mutation in the QRDR regions (gyrA, parC, and parE) (Figure 7a and 7b). The most common quinolone resistance gene profile observed is the "gyrA_D87N,gyrA_S83L,parC_S80I,parE_S458A", as observed in a quarter (n = 14/53) of isolates showing phenotypic resistance to ciprofloxacin. Ampicillin resistance among isolates belonging to 29 STs could be explained by the carriage of a range of beta-lactamase genes including bla_{TEM-1} (37/65 of isolates), bla_{TEM-40} (3 isolates), bla_{TEM-40} 84 (2 isolates), bla_{TEM-135} (2 isolates), bla_{TEM-215} (1 isolate), or bla_{OXA-2} (co-occurring with bla_{TEM-135} 90; 1 isolate). Extended-spectrum beta-lactam resistance likely resulted from bla_{CTX-M-15}, bla_{CTX} $_{M-27}$, and bla_{CMY-42} (Figure 8a and 8b) co-occurring largely with the plasmids Inc types FIB AP001918, FIA, IncFI, IncQ1, IncFII p, and the col plasmid Col156. All isolates were susceptible to ertapenem and meropenem (Table S2, Fig. S1a and S1b). One blactx-M-15 -positive isolate from LAU (ST11025, B1, O51:H12) was categorized as showing intermediate to imipenem but did not carry any carbapenemase-producing gene.

Of the 5 drug classes tested, the highest concordance between phenotypic resistance and predicted antimicrobial resistance was observed for trimethoprim (100% concordance, TP = 67/67, Sensitivity = 100%, Specificity = NA) and the lowest concordance for drugs within the

aminoglycoside class (concordance = 55.22%, TP = 37/67, Sensitivity = 100%, Specificity = 0 %) (Table S3a).

Multiple Antimicrobial Resistance

We observed a total of 23 resistance profiles (RP) (Table S1) with resistance profiles in many cases associated with specific STs (Table 1 and Table S4). Fifty-nine (88.06%) of the isolates were resistant to at least one agent within at least three classes of antibiotics, fitting the multidrug resistant (MDR) definition of the international AMR community [45] (Table S1). Forty-eight *E. coli* genomes carried genes conferring resistance to more than 5 antibiotic classes, including; cephalosporins, sulphonamides, tetracyclines, and aminoglycosides. The three most common beta-lactamase genes, bla_{TEM-1} , $bla_{CTX-M-15}$, and bla_{OXA-1} were carried by 37, 33, and 31 isolates belonging to 20 STs, 14 STs, and 11 STs, respectively. Isolates carrying the $bla_{CTX-M-15}$ gene also predominantly bore plasmid incompatibility group markers for FIB_AP001918 (n = 29/33), FIA (n = 24/33), FI (n = 20/33), and Col156 (n = 9). Isolates belonging to the most frequent sequence types form the bulk of invasive isolates carrying ESBL genes or mutations in the quinolone-resistance determining regions (*gyrA*, *parC*, *parE*), and the plasmid-mediated quinolone resistance gene aac(6')-*lb-cr*. Carbapenemase genes were conspicuously absent.

Resistance gene profiles differed significantly between the two ST131 clades. Unlike ST131 lineage 1 isolates, ST131 lineage 2 isolates did not carry any beta-lactamase gene besides *ampC*. Within the ST131 lineage 1, two isolates did not carry genes conferring resistance/reduced susceptibility to the aminoglycosides, phenicols, macrolides, and quaternary ammonium compounds. Furthermore, the absence of the Col156, IncB_O_K_Z, and IncFI plasmids in these two isolates seem to have been compensated by the possession of IncFIA, IncFII_p, and IncI1 plasmids, noted to have been absent in the other three ST131 isolates within the ST131 lineage 1.

All the ONovel32 strains (but not the co-clustering ONT strain) carried 1 ESBL gene $bla_{CTX-M-15}$, and these strains also carried IncF plasmids, common among phylogroup A strains (Table S4, Table S5). Every one of them carried the most common four resistance-conferring mutations in

the QRDRs (gyrA_D87N,gyrA_S83L,parC_S80I,parE_S458A) and seven, including the ONT strain, carried *qepA4*. Four ONovel32 isolates additionally carried *aac-(6')-Ib-cr*, conferring aminoglycoside and ciprofloxacin resistance, as well as horizontally-transmitted genes conferring resistance to trimethoprim, chloramphenicol and tetracyclines were common (Microreact link, Table S5).

Common to both the ST131 and the ONovel:32 clades is the high prevalence of *qacEdelta1* (n = 9 and 8, respectively) conferring resistance to quaternary ammonium compounds, commonly used for disinfecting hospital surfaces and associated with class 1 integrons. Altogether, these clades comprised 17 (42.50%) of 40 *E. coli* isolates carrying this gene.

ST131 and ONovel32 clade-specific genes

Pangenome analysis data of the 68 invasive isolates (Fig. 9) showed that of the 11715 gene clusters detected, 3084, 267, 2379, and 5985 gene clusters were classified as core genes (present in at least 67 out of 68), soft-core genes (present in 64-67 isolates), shell genes (9-64 isolates), and cloud genes (< 9 isolates), respectively. There were 90, 28, 55, 159, 11, and 81 accessory genes specific to the ST131 clade, ST156 clade, ST410 clade, ST648 clade, Onovel32 clade, and ST90 clade, respectively. The ONovel32 clade specific genes are predicted to encode surface factors (2), a ubiquinone biosynthesis O-methyltransferase, a transposase and hypothetical proteins (7).

The comparatively large number of accessory genes unique to the ST131 include prophage genes, adhesin genes, outer membrane-associated genes, DNA regulatory genes, IS transposase genes and associated enzymes, hypothetical genes (n = 60/90), as well as transporters of haemagglutinins, metals, and sugars. The two lineages of ST131 clade share 4116 core genes. On the one hand, isolates within the ST131 lineage 1 carried 121 accessory genes, including; mobile elements (group_1003, group_1164, group_1329, insB1, insCD1, ykfF, yjhR_2, ybcK, ybcQ, group_1340, rrrD), and genes involved in multi-drug efflux (emrE), DNA binding (arcA,

- argR_2), amino acid binding (argI_2), ATP binding (htpG_2, idnK), PTS permease activity
- 438 (frvA, frvB, sgcA_1), SOS response (umuC_4, group_1338). On the other hand, isolates within
- 439 the ST131 lineage 2 carried 284 accessory genes, including; prophage protein genes (gpFI_2),
- 440 mobile elements (group_1155, group_1348, group_1393, group_195, insN2, intS, nohB, pine,
- 441 rrQ, rzpD, ydfD, ynfO), and genes involved in structural molecule activity (flg, fli). A greater
- proportion of hypothetical genes were identified in lineage 2 (\sim 71%; n = 202/284) than lineage 1
- 443 (~38%; n = 47/121).
- Onovel32 clade isolates carried 11 unique accessory genes, mainly associated with outer surface
- structure including; the mitochondrial Ubiquinone biosynthesis O-methyltransferase, Spore coat
- protein SA, UDP-glucose:(glucosyl)LPS alpha-12-glucosyltransferase, IS5 family transposase
- 447 IS903, and 7 hypothetical proteins.

Discussion

448

449

- 450 This research characterized 68 bloodstream E. coli isolates as an important first step in
- 451 understanding their epidemiology within south-west Nigeria. In this small collection, we
- 452 identified multiple clones of pandemic importance, and found two predominant clades. One of
- 453 these, comprised of two ST131 lineages is globally disseminated and this study illustrates its
- 454 importance in Nigerian health facilities. The second predominant clade does not feature in
- present discourse on international ExPEC clones and represents strains belonging to ST10,
- 456 ST167 and related STs, which predominantly encode genes that could confer a novel O-antigen
- 457 type. In addition to these prominent clades, we identified strains belonging to major pandemic
- 458 ExPEC lineages, including ST12, ST73, and ST648, and their single locus variants. ST69,
- 459 ST95, and ST405 lineages were not detected but our sample is not very large and therefore our
- 460 findings are insufficient to rule them epidemiologically insignificant in our setting. We
- additionally identified in the collection four ST90 strains that appear to represent an outbreak,
- and related ST90 complex strains belonging to ST410. Our findings add to information that is
- chronicling ExPEC lineages of importance within Nigeria [14–16, 46, 47], other parts of Africa
- 464 [16, 48], and other low-middle-income countries [16, 49].

Among ST131, we found both globally-disseminated lineages within our isolate collection. The majority of haemolytic and pap gene bearing phylocgroup B2 strains belonged to this ST. Biofilm formation among these strains was common and associated with the *kpsD* gene, a known contributor to biofilm formation [50]. The ST10, ST167 and related strains that comprised the ONovel32 clade were distinguished by the presence of one of two variations of a capsular island that has been well described in *Klebsiella* with biofilm formation among them being more pronounced among strains carrying the *cpsACP*-containing portion of the island. While the virulence of ST131 has been well described, features of this clade that cause it to predominate remain unknown and further studies are required to understand its pathogenicity and selective success in our setting.

High levels of phenotypic resistance to antibiotics within the trimethoprim (co-trimoxazole), quinolone (nalidixic acid), fluoroquinolone (ciprofloxacin), cephalosporin (cefuroxime axetil), and the aminoglycosides (gentamicin) observed among invasive isolates in this study corroborates reports from previous studies [12, 46, 47] and pose a serious concern for clinical therapeutics. *In silico* data confirm the abundance of genes conferring resistance, with many isolates carrying more than one gene conferring resistance to a specific antimicrobial or class. Before the turn of the millennium, resistance to many of the aforementioned antimicrobials was rare in Africa. However, steady increase in the availability and use of these agents in the empiric treatment of ExPEC-related infections has inevitably selected for AMR. The increased rate of fluoroquinolone resistance in diarrhoeagenic *E. coli* and other enterobacteriaceae, for instance, coincided with increased usage of the fluoroquinolones in Nigeria [51] and other parts of Africa [7, 52]. While findings from a study conducted in Nigeria more than a decade ago [13] concluded that nalidixic acid was still an effective antimicrobial, we observed in this study that resistance to nalidixic acid is now common.

Similarly, cephalosporin resistance emerged and expanded much more in Africa than in other parts of the world as these agents became the drug of choice for treating multi-drug resistant pathogens [52]. Fluoroquinolone resistance has also been previously associated with the presence of ESBL genes because ESBL genes are often borne on transferable large plasmids that co-host some of the PMQR genes [53]. We observed the co-carriage of ESBL and fluoroquinolone

resistance genes in more than a quarter of the ExPEC isolates, and particularly in over-represented lineages.

We find that both predominant lineages we have highlighted in this report show multiple resistance. This has important implications for patients with life-threatening bloodstream infections and provides a plausible explanation for their evolutionary success in our setting. Resistance to antimicrobials used intensively in Nigeria (trimethoprim, aminopenicillins and ciprofloxacin) was rife and resistance to the agents most frequently used empirically when blood stream infections are suspected – second- and third-generation cephalosporins and aminoglycosides was also worryingly common. While none of these clades showed carbapenem or colistin resistance, these reserve antimicrobial classes are out of the reach of most patients attending the three hospitals from which the strains were obtained.

Next-generation sequencing has emerged as a promising complement to clinical bacteriology as it provides answers to medical conundrums as well as a more robust picture of the epidemiology of infectious diseases. It can also reveal, as in this case, circulation of hitherto unrecognized clones of concern. Although its integration into clinical diagnosis and patient care gaining ground many parts of the world, its adoption in LMICs (and the rest of the globe) is still hindered by lack of infrastructure, cost of implementing WGS, limited bioinformatics expertise and as yet mildly inaccurate prediction of antimicrobial resistance [54, 55]. In our study, we observed perfect concordance (100%) with phenotypic AST data for trimethoprim, but not for the cephalosporins, the quinolones, or the aminoglycosides. This therefore shows that further understanding of resistance mechanisms and routine AMR database update is needed to enhance the feasibility of gradual and sustained integration of WGS into routine diagnosis.

Another advantage of next-generation sequencing is its potential in rapid detection of outbreaks either retrospectively, or in real-time. We report a likely retrospective ST90 outbreak in LAU, which would not have been detected using traditional diagnostic methods in the sentinel laboratories. ST90 strains have variously been highlighted for their zoonotic potential and association with device-related hospital outbreaks [56–58] and its epidemiology in our setting remains to be understood. The adoption of genomic surveillance in diagnostic laboratories within Nigeria will ensure that outbreaks of this and other clones can be detected in real time,

while definite tracking and containment of the spread of such clones will be achieved before lives are lost. This study has a few limitations. Blood culture is infrequently performed in Nigerian hospitals and until recently, most isolates were not archived. Therefore, these isolates represent but a fraction of the ExPEC likely to have infected patients in the three hospitals and may not be representative. Our short-read data makes it impossible to accurately determine whether the resistance genes are located on the bacterial chromosome or plasmids (or other mobile genetic elements). For instance, pangenome analysis revealed that ST90 isolates (particularly the one with the larger pangenome) carried numerous prophage genes that might mediate exchange of AMR gene within and between clones and ONovel32 genomes are also phage-rich. ST131 isolates and other pandemic lineages also carried IS elements and mobile elements that can potentially transfer genes from chromosomes to plasmids (or vice versa) or between strains. However, we do not know whether these prophage genes or mobile genetic elements actually carried AMR genes observed. In future, we will incorporate long read sequencing into our prospective surveillance efforts in order to correctly identify plasmid-borne AMR genes. In conclusion, this study provided hospital-specific information on the population structure of ExPEC lineages needed to track pandemic lineages and guide infection disease control practices in line with Nigeria's national action plan on antimicrobial resistance. **Author Statements** Conceptualization: David M. Aanensen, Iruka N. Okeke, Chikwe Ihekweazu; Data curation: Ayorinde O. Afolayan, Anthony Underwood; Formal Analysis: Ayorinde O. Afolayan, Anthony Underwood, Oyeniyi S. Bejide, Iruka N. Okeke; Funding acquisition: David M. Aanensen, Aaron O. Aboderin, Iruka N. Okeke; **Investigation**: Ayorinde O. Afolayan, Abiodun Egwuenu, Erkison Ewomazino Odih, Oyeniyi S. Bejide, Aaron O. Aboderin, Iruka N. Okeke;

547

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

548

549

550

551

552

553

554

555

Methodology: Ayorinde O. Afolayan, Aaron O. Aboderin, Anderson O. Oaikhena, Erkison

Ewomazino Odih, Oyeniyi S. Bejide, Veronica O. Ogunleye, Adeyemi T. Adeyemo, Abolaji T.

Adeyemo, Anthony Underwood, Silvia Argimón, Monica Abrudan, David M. Aanensen, Iruka

N. Okeke; **Project administration**: Abiodun Egwuenu, Chikwe Ihekweazu, Aaron O. Aboderin,

Iruka N. Okeke; Resources: Anthony Underwood, Silvia Argimón, Veronica O. Ogunleye,

556 Adeyemi T. Adeyemo, Abolaji T. Adeyemo, David M. Aanensen, Iruka N. Okeke; Software: 557 Ayorinde O. Afolayan, Silvia Argimón, Anthony Underwood; **Supervision:** Aaron O. Aboderin, 558 Anthony Underwood, Silvia Argimón, David M. Aanensen, Iruka N. Okeke; Validation: All 559 authors; Visualization: Ayorinde O. Afolayan, Iruka N. Okeke; Writing – original draft: 560 Ayorinde O. Afolayan; **Writing – review & editing:** All authors. 561 562 Acknowledgments/Funding 563 We thank Damilola Q. Olaoye, Chinenye Ekemezie, Ifeoluwa Akintayo and Ifeoluwa Komolafe 564 for excellent technical assistance. 565 This work was supported by Official Development Assistance (ODA) funding from the National 566 Institute of Health Research [grant number 16_136_111] and the Wellcome Trust grant number 567 206194. INO was an African Research Leader supported by the UK Medical Research Council 568 (MRC) and the UK Department for International Development (DFID) under the MRC/DFID 569 Concordat agreement that is also part of the EDCTP2 program supported by the European 570 Union. The funders had no role in the content, crafting or submission of this paper. 571 572 **Ethics** 573 Isolates were obtained as part of the surveillance efforts in line with Nigeria's national action 574 plan and/or for bloodstream pathogen and Escherichia coli research. Ethical approval for 575 research using these isolates was obtained from the University of Ibadan/University College 576 Hospital and the Obafemi Awolowo University (OAU) Teaching Hospitals complex ethics 577 commitees. Respective IRB registration numbers are UI/EC/15/093 and ERC/2017/05/06. 578 579 **Conflicts of Interest** 580 The authors have no conflicts of interest to declare. 581 References 582 1. de Kraker MEA, Jarlier V, Monen JCM, Heuer OE, van de Sande N, et al. The 583 changing epidemiology of bacteraemias in Europe: Trends from the European

584 antimicrobial resistance surveillance system. Clin Microbiol Infect 2013;19:860–868. 585 2. **Forman B.** The epidemiology of urinary tract infection. *Nature Reviews Urology* 586 2010;7:653–660. 587 3. Manges AR, Geum HM, Guo A, Edens TJ, Fibke CD, et al. Global extraintestinal 588 pathogenic escherichia coli (Expec) lineages. Clin Microbiol Rev;32. Epub ahead of print 589 1 July 2019. DOI: 10.1128/CMR.00135-18. 590 4. Johnson JR, Russo TA. Molecular Epidemiology of Extraintestinal Pathogenic 591 Escherichia coli. *EcoSal Plus*;8. Epub ahead of print 8 February 2018. DOI: 592 10.1128/ecosalplus.esp-0004-2017. 593 5. Sarowska J, Futoma-Koloch B, Jama-Kmiecik A, Frej-Madrzak M, Ksiazczyk M, et 594 al. Virulence factors, prevalence and potential transmission of extraintestinal pathogenic 595 Escherichia coli isolated from different sources: Recent reports. Gut Pathogens 596 2019;11:10. 597 6. McNally A, Kallonen T, Connor C, Abudahab K, Aanensen DM, et al. Diversification 598 of colonization factors in a multidrug-resistant escherichia coli lineage evolving under 599 negative frequency-dependent selection. MBio;10. Epub ahead of print 1 March 2019. 600 DOI: 10.1128/mBio.00644-19. 601 7. Chattaway MA, Aboderin AO, Fashae K, Okoro CK, Opintan JA, et al. 602 Fluoroquinolone-resistant enteric bacteria in sub-saharan Africa: Clones, implications and 603 research needs. Frontiers in Microbiology 2016;7:558. 604 8. Alonso CA, Zarazaga M, Ben Sallem R, Jouini A, Ben Slama K, et al. Antibiotic 605 resistance in Escherichia coli in husbandry animals: the African perspective. Letters in 606 *Applied Microbiology* 2017;64:318–334. 607 Khairy RM, Mohamed ES, Abdel Ghany HM, Abdelrahim SS. Phylogenic 9. 608 classification and virulence genes profiles of uropathogenic E. coli and diarrhegenic E. 609 coli strains isolated from community acquired infections. *PLoS One* 2019;14:e0222441. 610 10. Forson AO, Tsidi WB, Nana-Adjei D, Quarchie MN, Obeng-Nkuramah N. 611 Escherichia coli bacteriuria in pregnant women in Ghana: Antibiotic resistance patterns 612 and virulence factors. BMC Res Notes 2018;11:901.

613 11. Huvnh BT, Padget M, Garin B, Herindrainv P, Kermorvant-Duchemin E, et al. 614 Burden of bacterial resistance among neonatal infections in low income countries: How 615 convincing is the epidemiological evidence? BMC Infect Dis 2015;15:127. 616 12. Seni J, Peirano G, Okon KO, Jibrin YB, Mohammed A, et al. The population structure 617 of clinical extra-intestinal Escherichia coli in a teaching hospital from Nigeria. Diagn 618 Microbiol Infect Dis 2018;92:46-49. 619 Okonko IO, Donbraye-Emmanuel OB, Ijandipe LA, Ogun AA, Adedeji AO, et al. 13. 620 Antibiotics Sensitivity and Resistance Patterns of Uropathogens to Nitrofurantoin and 621 Nalidixic Acid in Pregnant Women with Urinary Tract Infections in Ibadan, Nigeria. 622 *Middle-East J Sci Res* 2009;4:105–109. 623 14. Ogbolu DO, Piddock LJV, Webber MA. Opening Pandora's box: High-level resistance 624 to antibiotics of last resort in Gram-negative bacteria from Nigeria. J Glob Antimicrob 625 Resist 2020;21:211–217. 626 15. Duru C, Olanipekun G, Odili V, Kocmich N, Rezac A, et al. Molecular characterization 627 of invasive Enterobacteriaceae from pediatric patients in Central and Northwestern 628 Nigeria. PLoS One 2020;15:e0230037. 629 Sands K, Carvalho MJ, Portal E, Thomson K, Dyer C, et al. Characterization of 16. 630 antimicrobial-resistant Gram-negative bacteria that cause neonatal sepsis in seven low-631 and middle-income countries. Nat Microbiol 2021 64 2021;6:512–523. 632 17. Berends MS, Luz CF, Friedrich AW, Sinha BNM, Albers CJ, et al. AMR - An R 633 package for working with antimicrobial resistance data. bioRxiv 2019;810622. 634 18. CLSI. M100 Performance Standards for Antimicrobial Susceptibility Testing A CLSI 635 supplement for global application. Performance Standards for Antimicrobial Susceptibility 636 Testing Performance Standards for Antimicrobial Susceptibility Testing. 637 https://www.academia.edu/41587236/M100_Performance_Standards_for_Antimicrobial_ 638 Susceptibility_Testing_A_CLSI_supplement_for_global_application_28th_Edition (2020, 639 accessed 6 August 2020). 640 19. Wakimoto N, Nishi J, Sheikh J, Nataro JP, Sarantuya J, et al. Quantitative biofilm 641 assay using a microtiter plate to screen for enteroaggregative Escherichia coli. Am J Trop

642 *Med Hyg* 2004;71:687–690. 643 Naves P. Prado G Del, Huelves L, Gracia M, Ruiz V, et al. Measurement of biofilm 20. 644 formation by clinical isolates of Escherichia coli is method-dependent. J Appl Microbiol 645 2008;105:585–590. 646 21. Afolayan AO, Oaikhena AO, Aboderin AO, Olabisi OF, Amupitan AA, et al. Clones 647 and Clusters of Antimicrobial-Resistant Klebsiella from Southwestern Nigeria. bioRxiv 648 2021;2021.06.21.449255. 649 22. Croucher NJ, Page AJ, Connor TR, Delaney AJ, Keane JA, et al. Rapid phylogenetic 650 analysis of large samples of recombinant bacterial whole genome sequences using 651 Gubbins. Nucleic Acids Res 2015;43:e15. 652 23. Argimón S, Abudahab K, Goater RJE, Fedosejev A, Bhai J, et al. Microreact: 653 visualizing and sharing data for genomic epidemiology and phylogeography. Microb 654 genomics 2016;2:e000093. 655 24. Hadfield J, Croucher NJ, Goater RJ, Abudahab K, Aanensen DM, et al. Phandango: 656 an interactive viewer for bacterial population genomics. *Bioinformatics* 2018;34:292–293. 657 Inouve M, Dashnow H, Raven LA, Schultz MB, Pope BJ, et al. SRST2: Rapid genomic 25. 658 surveillance for public health and hospital microbiology labs. Genome Med 659 2014;6:006627. 660 26. **Ingle DJ, Levine MM, Kotloff KL, Holt KE, Robins-Browne RM**. Dynamics of 661 antimicrobial resistance in intestinal Escherichia coli from children in community settings in South Asia and sub-Saharan Africa. Nat Microbiol 2018;3:1063–1073. 662 663 27. Conway JR, Lex A, Gehlenborg N. UpSetR: An R package for the visualization of 664 intersecting sets and their properties. *Bioinformatics* 2017;33:2938–2940. 665 28. Hunt M, Mather AE, Sánchez-Busó L, Page AJ, Parkhill J, et al. ARIBA: Rapid 666 antimicrobial resistance genotyping directly from sequencing reads. *Microb Genomics*; 3. Epub ahead of print 1 October 2017. DOI: 10.1099/mgen.0.000131. 667 668 Chen L, Yang J, Yu J, Yao Z, Sun L, et al. VFDB: a reference database for bacterial 29. 669 virulence factors. DOI: 10.1093/nar/gki008.

- 670 30. Wirth T, Falush D, Lan R, Colles F, Mensa P, et al. Sex and virulence in Escherichia
- 671 coli: An evolutionary perspective. *Mol Microbiol* 2006;60:1136–1151.
- 672 31. Clausen PTLC, Aarestrup FM, Lund O. Rapid and precise alignment of raw reads
- against redundant databases with KMA. *BMC Bioinformatics* 2018;19:1–8.
- 674 32. Camacho C, Coulouris G, Avagyan V, Ma N, Papadopoulos J, et al. BLAST+:
- Architecture and applications. *BMC Bioinformatics*;10. Epub ahead of print 15 December
- 676 2009. DOI: 10.1186/1471-2105-10-421.
- 677 33. Beghain J, Bridier-Nahmias A, Nagard H Le, Denamur E, Clermont O.
- 678 ClermonTyping: An easy-to-use and accurate in silico method for Escherichia genus strain
- phylotyping. *Microb Genomics* 2018;4:e000192.
- 680 34. Kahlmeter G, Giske CG, Kirn TJ, Sharp SE. Point-counterpoint: Differences between
- the European Committee on Antimicrobial susceptibility testing and Clinical and
- Laboratory standards institute recommendations for reporting antimicrobial susceptibility
- results. *J Clin Microbiol*;57. Epub ahead of print 1 September 2019. DOI:
- 684 10.1128/JCM.01129-19.
- 685 35. **Schwengers**. Bakta: Rapid & standardized annotation of bacterial genomes & plasmids.
- 686 GitHub: https://github.com/oschwengers/bakta.
- 687 36. Rutherford K, Parkhill J, Crook J, Horsnell T, Rice P, et al. Artemis: sequence
- visualization and annotation. *Bioinformatics* 2000;16:944–945.
- 689 37. Carver TJ, Rutherford KM, Berriman M, Rajandream M-A, Barrell BG, et al. ACT:
- the Artemis comparison tool. *Bioinformatics* 2005;21:3422–3423.
- 691 38. Gilchrist CLM, Chooi Y-H. clinker & clustermap.js: automatic generation of gene
- cluster comparison figures. *Bioinformatics* 2021;37:2473–2475.
- 693 39. Arredondo-Alonso S, Rogers MRC, Braat JC, Verschuuren TD, Top J, et al.
- mlplasmids: a user-friendly tool to predict plasmid- and chromosome-derived sequences
- for single species. *Microb Genomics* 2018;4:e000224.
- 696 40. Tonkin-Hill G, MacAlasdair N, Ruis C, Weimann A, Horesh G, et al. Producing
- polished prokaryotic pangenomes with the Panaroo pipeline. *Genome Biol* 2020;21:180.

698 41. Schaufler K, Semmler T, Wieler LH, Trott DJ, Pitout J, et al. Genomic and functional 699 analysis of emerging virulent and multidrug-resistant Escherichia coli lineage sequence 700 type 648. Antimicrob Agents Chemother; 63. Epub ahead of print 1 June 2019. DOI: 701 10.1128/AAC.00243-19. 702 42. Fang CT, Chuang YP, Shun CT, Chang SC, Wang JT. A Novel Virulence Gene in 703 Klebsiella pneumoniae Strains Causing Primary Liver Abscess and Septic Metastatic 704 Complications. *J Exp Med* 2004;199:697–705. 705 43. Touzé T, Tran AX, Hankins J V, Mengin-Lecreulx D, Trent MS. Periplasmic 706 phosphorylation of lipid A is linked to the synthesis of undecaprenyl phosphate. Mol 707 Microbiol 2008;67:264. 708 Forde BM, Zowawi HM, Harris PNA, Roberts L, Ibrahim E, et al. Discovery of mcr-44. 709 1 -Mediated Colistin Resistance in a Highly Virulent Escherichia coli Lineage. 710 *mSphere*; 3. Epub ahead of print 31 October 2018. DOI: 10.1128/MSPHERE.00486-18. 711 45. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, et al. Multidrug-712 resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert 713 proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012;18:268-281. 714 715 Aboderin OA, Abdu LR, Odetoyin BW, Lamikanra A. Antimicrobial resistance in 46. 716 Escherichia coli strains from urinary tract infections. J Natl Med Assoc 2009;101:1268– 717 1273. 718 47. Onanuga A, Mahindroo J, Singh S, Taneja N. Phenotypic and molecular 719 characterization of antimicrobial resistant escherichia coli from urinary tract infections in 720 port-harcourt, nigeria. Pan Afr Med J;34. Epub ahead of print 2019. DOI: 721 10.11604/pamj.2019.34.144.18182. 722 48. Tegha G, Ciccone EJ, Krysiak R, Kaphatika J, Chikaonda T, et al. Genomic 723 epidemiology of Escherichia coli isolates from a tertiary referral center in Lilongwe, 724 Malawi. Microb Genomics 2020;7:000490. 725 Lim C, Takahashi E, Hongsuwan M, Wuthiekanun V, Thamlikitkul V, et al. 49. 726 Epidemiology and burden of multidrug-resistant bacterial infection in a developing

- 727 country. *Elife*;5. Epub ahead of print 6 September 2016. DOI: 10.7554/eLife.18082.
- 728 50. Russo TA, Wenderoth S, Carlino UB, Merrick JM, Lesse AJ. Identification, genomic
- organization, and analysis of the group III capsular polysaccharide genes kpsD, kpsM,
- kpsT, and kpsE from an extraintestinal isolate of Escherichia coli (CP9, O4/K54/H5). J
- 731 *Bacteriol* 1998;180:338–349.
- 732 51. Lamikanra A, Crowe JL, Lijek RS, Odetoyin BW, Wain J, et al. Rapid evolution of
- fluoroquinolone-resistant Escherichia coli in Nigeria is temporally associated with
- fluoroquinolone use. *BMC Infect Dis*;11. Epub ahead of print 7 November 2011. DOI:
- 735 10.1186/1471-2334-11-312.
- 736 52. Musicha P, Cornick JE, Bar-Zeev N, French N, Masesa C, et al. Trends in
- antimicrobial resistance in bloodstream infection isolates at a large urban hospital in
- 738 Malawi (1998–2016): a surveillance study. *Lancet Infect Dis* 2017;17:1042–1052.
- 739 53. **Rawat D, Nair D**. Extended-spectrum β-lactamases in gram negative bacteria. *J Glob*
- 740 Infect Dis 2010;2:263.
- 741 54. **Mitchell SL, Simner PJ**. Next-Generation Sequencing in Clinical Microbiology: Are We
- There Yet? *Clinics in Laboratory Medicine* 2019;39:405–418.
- 743 55. **Rossen JWA, Friedrich AW, Moran-Gilad J**. Practical issues in implementing whole-
- 744 genome-sequencing in routine diagnostic microbiology. Clinical Microbiology and
- 745 *Infection* 2018;24:355–360.
- 746 56. **Borges CA, Tarlton NJ, Riley LW**. Escherichia coli from Commercial Broiler and
- 747 Backyard Chickens Share Sequence Types, Antimicrobial Resistance Profiles, and
- Resistance Genes with Human Extraintestinal Pathogenic Escherichia coli. *Foodborne*
- 749 *Pathog Dis* 2019;16:813–822.
- 750 57. Gauthier L, Dortet L, Cotellon G, Creton E, Cuzon G, et al. Diversity of
- 751 carbapenemase-producing Escherichia coli isolates in France in 2012-2013. *Antimicrobial*
- 752 Agents and Chemotherapy;62. Epub ahead of print 1 August 2018. DOI:
- 753 10.1128/AAC.00266-18.
- 754 58. Sartori L, Fernandes MR, Ienne S, de Souza TA, Gregory L, et al. Draft genome
- sequences of two fluoroquinolone-resistant CTX-M-15-producing Escherichia coli ST90

 (ST23 complex) isolated from a calf and a dairy cow in South America. *Journal of Global Antimicrobial Resistance* 2017;11:145–147.


Figures and Tables

Table 1: Distribution of Sequence Types (ST) and Resistance Profiles (RP) within Sentinel

Sites

	No. of		Most		Most Prevalent Resistance Profile
Site	Isolates	Observed	Prevalent	Observed	(total number, STs (number))
		STs	ST	Resistance	
			(number)	Profile	
OAU	18	10	ST131 (6)	9	RP-1: AMP CIP CRO CXM CXMA
					GEN NAL SXT ($n = 5$; ST131 ($n =$
					3))
UCH	22	15	ST131 (5)	14	RP-5: AMP SXT (n = 4, ST12 (n =
					2), ST942 (n = 2))
LAU	28	18	ST156 (4)	14	RP-2: AMP CIP CXMA GEN NAL
			& ST90		SXT (Total = 7 , ST156 (n = 3),
			(4)		ST90 $(n = 3)$)





767 B





Figure 1a: Maximum likelihood SNP tree of bloodstream *E. coli* isolates sequenced for this study. Leaf tip colours differentiate the sentinel sites. The red box indicates the multisite ST131

clade and the ST10-ST167 clade is boxed in blue. A brown box marks the cluster from a single site representing likely outbreak clone of ST90 (b) The ST90 likely outbreak cluster of O8:H9 strains, showing resistance and plasmid profiles

b: A likely outbreak clone of ST90 in a sentinel hospital. Legend shows serotype, resistance profile and plasmid profile of ST90 *E. coli* isolates.

779 A.



781 B





Fig. 2: a. Comparison of virulence genes among isolates clustered within phylogroups A-F. Graph shows the prevalence of virulence factors in isolates within phylogroups A (n = 18), phylogroup B1 (n = 15), phylogroup B2 (n = 19), phylogroup C (n = 8), phylogroup D (n = 2), phylogroup E (n = 1), and phylogroup F (n = 5). Using Fisher's test (p < 0.05), only the virulence

genes significantly more prevalent in the phylogroups are shown. B. Biofilm formation in a subset of strains, measured as A570 nm of crystal violet eluted from fixed and stained six-hour biofilms. Each dot represents data from a single strain belonging to the phylogroup listed on the X axis. Horizontal bars mark the median for each phylogroup, outliers inclusive due to the small number of tested strains in each phylogroup.

793 A




795 B



Fig. 3a: Comparison of virulence genes between ST131 (n = 12) and non-ST131 (n = 35) isolates. Non-ST131 isolates refer to isolates within STs 10, 156, 167, 410, 648, 90, 11025, 12, 1642*, 450, and 942. Using Fisher's test (p < 0.05), only the virulence genes significantly more prevalent in the STs are shown.

b: Virulence factor profile of isolates belonging to ST131. Leaf tip colours differentiate the sentinel sites; OAU (Red), UCH (Blue), LAU (Yellow). The presence or absence of a virulence gene is indicated by a red or white colour on the heatmap, respectively.

805 A



807 B

806

809





Fig. 4a: Comparison of virulence genes between Onovel32 (n = 11) and non-Onovel32 (n = 57) clade isolates. Using Fisher's test (p < 0.05), only the virulence genes significantly more

prevalent are shown. The cpsACP gene and the ugd gene bars were coloured red and magenta, respectively.

b: Onovel32 clade isolates belonging to the sequence types ST10, ST167, and their locus variants belong to phylogroup A. Leaf tip colours differentiate the sentinel sites; OAU (Red), UCH (Blue), LAU (Yellow).

817 A



819 B




Figure 5a: Schematic cluster in ST1294 ONovel32 chromosome that includes the *ugd* and *cpsACP* genes. The 171 genes within the cluster are syntenic and identical with a cluster from *Klebsiella variicola* (Accession number: <u>CP079802.1</u>). Above the schematic depiction of genes is a G+C content plot and mutational response index plot. (b) comparison of the ONovel32 cluster with analogous cluster in *Klebsiella variicola* strain EMBL-1





Fig. 6a: Resistance Profile of ExPEC isolates. The main bar chart demonstrates the number of ExPEC isolates with each combination of resistance to tested antibiotics, and is ordered in

descending order by the frequency of resistance profiles observed among 67 ExPEC isolates. The side bar chart demonstrates the number of isolates that are resistant to each of the named antibiotics. The dots and lines between dots at the base of the main bar chart (and the right side of the side bar chart) show the co-resistance status of the ExPEC isolates. All isolates were susceptible to Amikacin, Meropenem, Imipenem, and Ertapenem.

AMP = Ampicillin; CIP = Ciprofloxacin; CRO = Ceftriaxone; CXM = Cefuroxime; CXMA = Cefuroxime Axetil; FEP = Cefepime; GEN = Gentamicin; NAL = Nalidixic Acid; NIT = Nitrofurantoin; SFP = Cefoperazone/Sulbactam; SXT = Trimethoprim/Sulfamethoxazole; TZP = Piperacillin/Tazobactam

Fig. 6b: AMR phenotypes of ExPEC Isolates, stratified by Sentinel Site (LAU (n = 28), OAU (n = 22), UCH (n = 21)). The size of the coloured circles represent the proportion of isolates recovered from each sentinel site that demonstrated resistance to the tested antibiotics.







Fig. 7: Quinolone resistance gene combinations in ExPEC isolates. The upset plots show (a, b) the number of ExPEC isolates carrying each combination of genes conferring resistance to the quinolones (b), and is coloured by the proportion of observed phenotypic antimicrobial susceptibility, and is ordered in descending order by the frequency of resistance gene profiles observed. The side bar chart demonstrates the number of isolates that carry each of the resistance genes. The dots and lines between dots at the base of the main bar chart (and the right side of the side bar chart) show the co-resistance gene profile of the ExPEC isolates. From the legend of the coloured upset plot, NA means that phenotypic antimicrobial susceptibility data for the isolate is absent.





861 b.)




Fig. 8: ESBL genes in ExPEC isolates. The upset plots demonstrate (a, b) the number of ExPEC isolates carrying each combination of genes conferring resistance to cephalosporins and (b), is coloured by the proportion of observed phenotypic antimicrobial susceptibility, and is ordered in

descending order by the frequency of resistance gene profiles observed. The side bar chart (a) demonstrates the number of isolates that carry each of the resistance genes. The dots and lines between dots at the base of the main bar chart (and the right side of the side bar chart) show the co-resistance gene profile of the ExPEC isolates. From the legend of the coloured upset plot, NA means that there is no available data on phenotypic antimicrobial susceptibility data for the isolate.




Fig. 9: Maximum-likelihood phylogeny, core and accessory genome profiles of 68 invasive *E. coli* whole-genome sequences visualized in combination with metadata (from left to right: Sentinel, ST, phylogroup, biofilm index, haemolysis type, morphology, Serotype, and AMR gene profiles). Presence of an AMR gene belonging to the named antibiotic class is indicated by a maroon colour, while absence is indicated by a grey colour. Presence of a gene in the pangenome is indicated by a blue colour while absence is indicated by a white colour. Highlighted pangenome section show that ST131 (top) and ONovel32 (bottom) isolates have large pangenomes.

Supplementary Tables

Table S1: Resistance profiles of ExPEC isolates

Decistance Drofile (number)	Resistance Profile code
Resistance Profile (number)	
AMP CIP CRO CXM CXMA GEN NAL SXT (10)	RP-1
AMP CIP CXMA GEN NAL SXT (8)	RP-2
AMP CIP CRO CXM CXMA FEP GEN NAL SXT (6)	RP-3
AMP CIP NAL SXT (6)	RP-4
AMP SXT (4)	RP-5
SXT (4)	RP-6
AMP CIP CRO CXM CXMA FEP GEN NAL SFP SXT TZP (3)	RP-7
AMP CIP CRO CXM CXMA FEP NAL SXT (3)	RP-8
AMP CIP CRO CXM CXMA NAL SXT (3)	RP-9
AMP NAL SXT (3)	RP-10
AMP CIP CRO CXM CXMA FEP GEN NAL NIT SXT (2)	RP-11
AMP CIP CRO CXM CXMA FEP GEN NAL SXT TZP (2)	RP-12
AMP CIP CXM CXMA NAL SXT TZP (2)	RP-13
AMP CIP CXMA GEN NAL NIT SXT (2)	RP-14
AMP CIP CRO CXM CXMA GEN NAL SXT TZP (1)	RP-other
AMP CIP CRO CXM CXMA SXT (1)	RP-other
AMP CIP CRO CXM CXMA GEN NAL SXT TZP (1)	RP-other
AMP CIP CXMA NAL SXT (1)	RP-other
AMP CIP CXMA NAL SXT TZP (1)	RP-other
AMP CIP GEN NAL SXT (1)	RP-other
AMP CXMA SXT (1)	RP-other
AMP GEN NAL SXT TZP (1)	RP-other
NAL SXT TZP (1)	RP-other

Table S2: Summary of Antibiotic Susceptibility Test data showing the number of *E. coli* isolates that were resistant to the named antibiotics.

Drug class	Drug	Resistance % (resistance (n)/species (n))				
Aminoglycosides	Gentamicin (GEN)	55.20% (37/67)				
Beta-lactams/penicillins	Ampicillin (AMP)	92.50% (62/67)				
	Piperacillin/tazobactam (TZP)	17.90% (12/67)				
Cephalosporins (2nd gen.)	Cefuroxime (CXM)	50.70% (34/67)				
	Cefuroxime Axetil (CXMA)	70.10% (47/67)				
Cephalosporins (3rd gen.)	Cefoperazone.Sulbactam (SFP)	4.50% (3/67)				
	Ceftriaxone (CRO)	46.30% (31/67)				
Cephalosporins (4th gen.)	Cefepime (FEP)	23.90% (16/67)				
Other antibacterials	Nitrofurantoin (NIT)	6.00% (4/67)				
Quinolones	Ciprofloxacin (CIP)	79.10% (53/67)				
	Nalidixic acid (NAL)	85.10% (57/67)				
Trimethoprims	Trimethoprim/sulfamethoxazole (SXT)	100.0% (67/67)				

medRxiv preprint doi: https://doi.org/10.1101/2021.11.07.21265989; this version posted November 11, 2021. The copyright holder for this preprint (which was not certified by beer review) is the authbr/funder, who has granted medRxiv a license to display the preprint in perpetuity.

All rights reserved. No reuse allowed without permission.

Table S3: Degree of Agreement between phenotypic antimicrobial susceptibility tests and genotypic predicted antimicrobial resistance

drug	Tests (N)	concordance	TP	FP	TN	FN	specificity	Specificity lower	Specificity upper	sensitivity	Sensitivity lower	Sensitivity upper limits
								limits	limits		limits	
Aminoglycosides	67	0.552238806	37	30	0	0	0	0	0.1157033 08	1	0.90510941 3	1 All rig
Beta-lactams	67	0.71641791	45	1	3	18	0.75	0.19412045	0.9936905 37	0.71428571 4	0.58653897 4	0.821070793 reserved.
Cephalosporins	67	0.686567164	46	20	0	1	0	0	0.1684334 71	0.97872340 4	0.88706228 3	0.999461468 So
Quinolones	67	0.865671642	56	7	2	2	0.22222222	0.02814497	0.6000935 74	0.96551724 1	0.88092268 9	0.995796353
Trimethoprim	67	1	67	0	0	0	NA	0	1	1	0.94643034 6	0.995796353 allowed without permiss

medRxiv preprint doi: https://doi.org/10.1101/2021.11.07.21265989; this version posted November 11, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

All rights reserved. No reuse allowed without permission.

(Table S3b). Degree of Agreement between phenotypic antimicrobial susceptibility tests and genotypic predicted antimicrobial resistance in isolates belonging to the ST131, ST90, and ST10-167 clades.

id	ST	Amin oglyco	Amino glycosi	Betalacta m	Betalac tam	Cephal osporin	Cephal osporin	Quin olone	Quin olone	Trime thopri	Trime thopri
		sides	des	AMR	AST	S	S	S	S	m	m
		AMR	AST			AMR	AST	AMR	AST	AMR	AST
G18484079	1284	R	S	S	R	R	R	R	R	R	R
G18503180	131	R	R	S	R	R	R	R	R	R	R
G18503191	131	R	S	S	R	R	R	R	R	R	R
G18503409	131	R	R	R	R	R	R	R	R	R	R
G18503422	131	R	R	R	R	R	R	R	R	R	R
G18503432	131	R	R	R	R	R	R	R	R	R	R
G18584035	131	R	R	S	R	R	R	R	R	R	R
G18584046	131	R	R	S	R	R	R	R	R	R	R
G18584087	131	R	S	R	R	R	S	R	R	R	R
G18584153	131	R	R	S	R	R	R	R	R	R	R
G18584154	131	R	R	S	R	R	R	R	R	R	R
G18584155	131	R	S	R	S	R	S	R	S	R	R
G18584158	10	R	R	R	R	R	R	R	R	R	R
G18584159	167	R	R	R	R	R	R	R	R	R	R

G18584161	167	R	R	R	R	R	R	R	R	R	R
G18584163	10	R	R	R	R	R	R	R	R	R	R
G18600004	10	R	S	R	R	R	R	R	R	R	R
G18600024	131	R	R	S	R	R	R	R	R	R	R
G18600026	167	R	R	R	R	R	R	R	R	R	R
G18600033	617	R	R	S	R	R	R	R	R	R	R
G18600048	44	R	R	S	R	R	R	R	R	R	R
GI8584164	10	R	S	R	R	S	R	R	R	R	R
G18600002	90	R	R	R	R	R	R	R	R	R	R
G18600020	90	R	R	R	R	R	R	R	R	R	R
G18600022	90	R	R	R	R	R	R	R	R	R	R
G18600030	90	R	R	R	R	R	R	R	R	R	R

Table S4: Genotypic characteristics of the most common STs in the invasive microbial population.

ST (number of strains)	Phylo- group	Sentinel Site (number)	Serotype (number)	Most Prevalent Resistance Profile (number)	Most Prevalent AMR gene profile (number)	Most prevalent plasmid replicon profile (number)
ST131	B2	OAU (6)	O16:H5 (5),	RP-1: AMP CIP	aac(6')-Ib-cr5; Aac3-IIa*,Aac6Ib-cr*,AadA5; blaCTX-	Col156;
(12)		UCH (5) LAU (1)	O25:H4 (7)	CRO CXM CXMA GEN NAL SXT (5)	M-15,blaEC-5,blaOXA-1; CatB4_602; DfrA17; gyrA_D87N,gyrA_S83L,parC_E84V,parC_S80I,parE_I 529L; MphA_1663; qacEdelta1; SulI; TetA (n = 3) and	IncB_O_K_Z; IncFI; IncFIB_AP001918 (3) and
					aac(6')-Ib-cr5; Aac3-IId*,Aac6Ib-cr*,AadA5,StrA*,StrB*; blaCTX-M-15,blaEC-5,blaOXA-1; blaTEM-40; CatB4; DfrA17; gyrA_S83L,parE_I529L; MphA; qacEdelta1; SulII,SulI; TetA (3)	Col156; IncFI; IncFIA; IncFIB_AP001918 (3)
ST10 (4)	A	OAU (3) LAU (1)	Onovel32:H 10 (3), H10 (1)	RP-14: AMP CIP CXMA GEN NAL NIT SXT (2)	Each isolate had a unique AMR gene profile	IncFI; IncFIA; IncFIB_AP001918; IncQ1 (2)
ST156 (5)	B1	LAU (4) UCH (1)	H45 (1), O174:H28 (1), O54:H28 (2),	RP-2: AMP CIP CXMA GEN NAL SXT (3)	Aac3-IId*,StrA*,StrB; blaEC-18; blaTEM-1; DfrA17; gyrA_D87N,gyrA_S83L,parC_S80I; qepA8; SulII*; TetB*(3)	IncFIA; IncFIB; IncQ1 (3)

			O76:H30 (1)			
ST167	A	OAU (2)	Onovel32:H	Each isolate had a	Aac3-IId*; blaCTX-M-15,blaEC-15; blaTEM-1;	IncFI; IncFIA;
(4)		LAU (1)	10 (2),	unique AST profile	gyrA_D87N,gyrA_S83L,parC_S80I,parE_S458A;	IncFIB_AP001918
		UCH (1)	Onovel32:H		TetB* (2)	(3)
			21 (2)			
ST410	C	LAU (2)	O8:H9 (2),	RP-9: AMP CIP	Each isolate had a unique AMR gene profile	Col_MG828; IncFI;
(4)		UCH (2)	Onovel14:H	CRO CXM CXMA		IncFIA;
			9 (2)	NAL SXT (2)		IncFIB_AP001918
						(2)
ST648	F	LAU (3)	O153var1:H	RP-7: AMP CIP	aac(6')-Ib-cr5; Aac3-IIa*,Aac6Ib-cr*,AadA5; blaCMY-	Col_BS512;
(4)		OAU (1)	6 (1), O8:H4	CRO CXM CXMA	42,blaCTX-M-15,blaEC-19,blaOXA-1; blaTEM-1;	
			(3)	FEP GEN NAL SFP	CatA1*,CatB4; DfrA17;	,
				SXT TZP (2)	gyrA_D87N,gyrA_S83L,parC_S80I,parE_S458A;	IncFIB_AP001918;
					MphA; qacEdelta1; SulI; TetB* (2).	IncFII_p; IncI1 (2)
ST90	C	LAU (4)	O8:H9 (4)	RP-2: AMP CIP	aac3-IId, aac6Ib-cr, strA, strB; blaTEM-1; blaEC-16,	IncFI; IncFIA;
(4)				CXMA GEN NAL	· 63 = · · 63 = · · · 1 = · ·	IncFIB_AP001918;
				SXT (3)	parE_S458A; dfrA17; mphA; sulII; tetB (4).	IncQ1 (4)
ST1102	B1	LAU (2)	O51:H12 (2)	RP-11: AMP CIP	aac3-IIa, aadA5, strA, strB; blaTEM-1; blaCTX-M-15,	IncFIA;
5 (2)				CRO CXM CXMA	blaEC-16; gyrA_D87N, gyrA_S83L, parC_S80I,	IncFIB_AP001918;
				FEP GEN NAL NIT	parE_S458T; catA1; dfrA17; sulII; tetB; qacE (2)	IncFII_p; IncI1;
				SXT (1)		IncQ1 (2)
				and		

				RP-other		AMP			
ST12 (2)	B2	UCH (2)	O4:H1 (2)	RP-5: Al	MP SX	T (2)	strA, strB; blaTEM-1; blaCTX-M-15, blaEC-5; gyrA_S83L; dfrA7; sulI, sulII; tetA; qacEdelta1 (2)	IncQ1; IncY (2	2)
ST1642 * (2)	B1	OAU (1) UCH (1)	O8:H7 (2)	RP-1: CRO CZ GEN NA and RP-4: NAL SX	XM CX AL SXT AMP	XMA		Col8282; IncFIA; IncFIB_AP001 IncFII; IncQ1	IncFI;
ST450 (2)	A	LAU (1) UCH (1)	O12:H16 (1), O45:H16 (1)	RP-4: NAL SX		CIP	aadA5, strA, strB; blaTEM-1; blaEC-15; gyrA_D87N, gyrA_S83L, parC_S80I, parE_I464F/ parE_S458A; CatA1; dfrA17; sulII; tetA; qacEdelta1	Col_BS5121 Col_MG828; IncFIA; IncFIB_AP001 IncFII_p (1);	1;
								OR Col156; IncFIA; IncFIB_AP001 (1)	IncFI; 1918

ST942 B1	UCH (2) O163:H28	RP-5: AMP SXT (2)	strA, strB; blaTEM-1; blaEC-16; qnrS1; floR; sulII; tetA pO111 (2)
(2)	(2)		(2)

Table S5: Genotypic characteristics of Onovel32 genomes in the invasive microbial population.

id	Sentinel	ST	Serotype	Resistance gene profile	plasmid_profile
G18484079	OAU	1284	Onovel32:H21	AadA2*, StrA*?,StrB; blaCTX-M-15,blaEC-15; CatA2*; DfrA12; gyrA_D87N,gyrA_S83L,parC_S80I,parE_S458A; MphA; qacEdelta1; qepA4; SulII, SulI; TetB*	IncFI; IncFIA; IncFIB_AP001918; IncX1; IncX1_1
G18503408	UCH	167	Onovel32:H10	AadA2*,StrA*,StrB*; blaCTX-M-27, blaEC-15; CatA1*,CatA2*; DfrA12; gyrA_D87N,gyrA_S83L,parC_S80I,parE_S458A; MphA*?; qacEdelta1; qepA4; SulII, SulI; TetA,TetB*,TetM*	IncFI; IncFIA; IncFIB_AP001918; IncX2
G18584158	OAU	10	Onovel32:H10	aac(6')-Ib-cr5; Aac3-IId*,Aac6Ib-cr*,AadA5,StrA*,StrB; blaOXA-1; blaTEM-84; CatA1*,CatB4; DfrA17; gyrA_D87N,gyrA_S83L,parC_S80I,parE_S458A; MphA; qacEdelta1; SulII*; TetB*	IncFI; IncFIA; IncFIB_AP001918; IncQ1
G18584159	OAU	167	Onovel32:H21	Aac3-IId*; blaCTX-M-15, blaEC-15; blaTEM-1; gyrA_D87N,gyrA_S83L,parC_S80I,parE_S458A; TetB*	IncFI; IncFIA; IncFIB_AP001918
G18584161	OAU	167	Onovel32:H21	Aac3-IId*; blaCTX-M-15, blaEC-15; blaTEM-1;	IncFI; IncFIA;

				gyrA_D87N,gyrA_S83L,parC_S80I,parE_S458A; TetB*	IncFIB_AP001918
G18584163	OAU	10	Onovel32:H10	aac(6')-Ib-cr5; Aac3-IId*,Aac6Ib-cr*,AadA5,StrA*,StrB; blaOXA-1; blaTEM-84; CatA1*,CatB4*; DfrA17; gyrA_D87N,gyrA_S83L,parC_S80I,parE_S458A; MphA; qacEdelta1; SulII*; TetB*	IncFI; IncFIA; IncFIB_AP001918; IncQ1
G18600004	LAU	10	Onovel32:H10	AadA1*?,StrA*,StrB*; blaOXA-1; blaTEM-1; DfrA14; gyrA_D87N,gyrA_S83L,parC_S80I,parE_S458A; qepA4; SulII	IncFI; IncFIA; IncFIB_AP001918
G18600026	LAU	167	Onovel32:H10	Aac3-IId*; blaEC-15; blaTEM-1; CatA1*; DfrA12; gyrA_D87N,gyrA_S83L,parC_S80I,parE_S458A; MphA; qacEdelta1; qepA4; SulI; TetB*	IncFI; IncFIA; IncFIB_AP001918
G18600033	LAU	617	Onovel32:H10	aac(6')-Ib-cr5; Aac3-IIa*,Aac6Ib-cr*,AadA5,StrA*?,StrB; blaCTX-M-15,blaEC-15,blaOXA-1; CatB4; DfrA17; gyrA_D87N,gyrA_S83L,parC_S80I,parE_S458A; MphA; qacEdelta1; SulII, SulI; TetB*	IncFI; IncFIA; IncFIB_AP001918
G18600048	LAU	44	Onovel32:H4	aac(6')-Ib-cr5; Aac3-IIa*,Aac6Ib-cr*,AadA5;	Col_MG828; IncFI;

			blaCTX-M-15,blaOXA-1;	CatB4;	DfrA17;	IncFIB_AP001918; IncX3
			gyrA_D87N,gyrA_S83L,parC	S458T;		
			qacEdelta1; SulI; TetB*			
GI8584164 OAU	10	H10	AadA2*,StrA*,StrB,CatA1*; gyrA_D87N,gyrA_S83L,parC MphA,QepA2*; qacEdelta1; TetB*	C_S80I,parE_	S458A;	ColRI; Col_BS512; IncP_6